Literature DB >> 25936872

Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.

Mads Emil Bjørn1,2, Morten Orebo Holmström1, Hans Carl Hasselbalch1.   

Abstract

We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 10(9)/L) during their treatment-course. The majority of the patients experienced marked clinical improvement. Serious side effects were only recorded in a single patient. It is concluded that JAK-inhibition with ruxolitinib is manageable in patients with low platelet counts and should be considered in symptomatic patients who otherwise might not be candidates for treatment.

Entities:  

Keywords:  Bleeding; JAK2V617F; myelofibrosis; ruxolitinib; thrombocytopenia

Mesh：

Substances：

Year:  2015        PMID： 25936872     DOI： 10.3109/10428194.2015.1046867

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


  4 in total

1.  Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.

Authors:  Lucia Masarova; Ahmad Alhuraiji; Prithviraj Bose; Naval Daver; Naveen Pemmaraju; Jorge Cortes; Sherry Pierce; Hagop Kantarjian; Srdan Verstovsek
Journal:  Eur J Haematol       Date:  2018-01-17       Impact factor: 2.997

2.  Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Authors:  Allison H Scotch; Heidi Kosiorek; Robyn Scherber; Amylou C Dueck; Stefanie Slot; Sonja Zweegman; Peter A W Te Boekhorst; Suzan Commandeur; Harry Schouten; Federico Sackmann; Ana Kerguelen Fuentes; Dolores Hernández-Maraver; Heike L Pahl; Martin Griesshammer; Frank Stegelmann; Konstanze Döhner; Thomas Lehmann; Karin Bonatz; Andreas Reiter; Francoise Boyer; Gabriel Etienne; Jean-Christophe Ianotto; Dana Ranta; Lydia Roy; Jean-Yves Cahn; Claire N Harrison; Deepti Radia; Pablo Muxi; Norman Maldonado; Carlos Besses; Francisco Cervantes; Peter L Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Chiara Paoli; Francesco Passamonti; Bjorn Andreasson; Maria L Ferrari; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Zhijian Xiao; Zefeng Xu; Yue Zhang; Xiujuan Sun; Junqing Xu; Jean-Jacques Kiladjian; Peihong Zhang; Robert Peter Gale; Ruben A Mesa; Holly L Geyer
Journal:  Leuk Res       Date:  2017-10-14       Impact factor: 3.156

3.  Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.

Authors:  Thamer Sliwa; Christine Beham-Schmid; Sonja Burgstaller; Veronika Buxhofer-Ausch; Günther Gastl; Klaus Geissler; Maria Krauth; Peter Krippl; Alois Lang; Andreas Petzer; Stefan Wöhrer; Albert Wölfler; Heinz Gisslinger
Journal:  Wien Klin Wochenschr       Date:  2016-12-13       Impact factor: 1.704

4.  Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene.

Authors:  Grzegorz Helbig; Ryszard Wichary; Karolina Torba; Sławomira Kyrcz-Krzemień
Journal:  Med Oncol       Date:  2017-01-24       Impact factor: 3.064
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.